Article
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
Rating:
0.0
Views:
77
Likes:
1
Library:
1
A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could assess potential safety risks of their sickle cell disease gene therapy after approval.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value